Zunveyl Tablet, Delayed Release
Product Images NDC 84054-015

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Zunveyl (NDC 84054-015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alpha Cognition, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zunveyl 01)

Chemical structure of benzgalantamine, the active ingredient in ZUNVEYL tablets. The diagram displays molecular bonds and ring structures characteristic of the benzgalantamine compound.*

FDA Label Image

Figure 1 (Zunveyl 02)

A line graph depicting mean change from baseline in ADAS-cog score over 21 weeks of treatment. The vertical axis ranges from -3 to 3, with negative values indicating improvement and positive values indicating decline. Four lines represent Placebo, 8 mg/day, 16 mg/day, and 24 mg/day treatment groups, showing cognitive performance trends over time with error bars for standard error.*

FDA Label Image

Figure 2 (Zunveyl 03)

A cumulative percentage of patients graph illustrating ADAS-cog change from baseline. The x-axis shows ADAS-cog change values from -15 to 15, while the y-axis displays cumulative percentages from 0 to 100%. Four groups are compared: Placebo, 8 mg/day, 16 mg/day, and 24 mg/day, with markers indicating different response levels in patients across these doses.*

FDA Label Image

Figure 3 (Zunveyl 04)

A bar chart displaying the percentage of patients according to CIBIC-plus Rating categories for Placebo, 8 mg/day, 16 mg/day, and 24 mg/day dosing groups. The categories range from Markedly Improved to Markedly Worse, with the largest percentages in No Change and Minimally Worse categories.*

FDA Label Image

Figure 4 (Zunveyl 05)

A line graph showing mean change from baseline in ADAS-cog score over 26 weeks of treatment, comparing placebo with benzgalantamine at 24 mg/day and 32 mg/day doses. The graph illustrates cognitive improvement for the benzgalantamine groups and decline for placebo over time.*

FDA Label Image

Figure 5 (Zunveyl 06)

A cumulative percentage graph showing ADAS-cog change from baseline versus percentage of patients for placebo, 24 mg/day, and 32 mg/day treatment groups. The x-axis ranges from -15 to 15 points of ADAS-cog change, and the y-axis represents cumulative percentage of patients from 0 to 100%. Vertical lines mark changes at -10, -7, -4 points, and no change at 0.*

FDA Label Image

Figure 6 (Zunveyl 07)

A bar chart depicting clinical outcomes based on CIBIC-plus Rating categories for three groups: Placebo, 24 mg/day, and 32 mg/day doses. The vertical axis shows the percentage of patients, and the horizontal axis lists rating categories from Markedly Improved to Markedly Worse. Bars compare patient percentages across treatments within each category.*

FDA Label Image

Figure 7 (Zunveyl 08)

A line graph showing mean change from baseline in ADAS-cog scores over 26 weeks of treatment. The x-axis represents weeks of treatment (0, 3, 13, 26), and the y-axis shows mean change from baseline in ADAS-cog scores, where negative values indicate improvement and positive values indicate decline. The graph compares three groups: placebo, 24 mg/day, and 32 mg/day doses, with error bars indicating standard error. Both 24 mg/day and 32 mg/day groups show improvement over time, while the placebo group shows decline.*

FDA Label Image

Figure 8 (Zunveyl 09)

A cumulative percentage of patients chart showing ADAS-cog change from baseline on the x-axis ranging from -15 to 15, and cumulative percentage of patients on the y-axis ranging from 0 to 100%. The chart compares three groups: Placebo (open circles), 24 mg/day dose (black squares), and 32 mg/day dose (black triangles). Vertical reference lines indicate -10 points, -7 points, -4 points, and no change on the x-axis.*

FDA Label Image

Figure 9 (Zunveyl 10)

A bar chart showing the distribution of CIBIC-plus Rating scores among patients, categorized by treatment groups: Placebo, 24 mg/day, and 32 mg/day doses of ZUNVEYL (benzgalantamine). The y-axis depicts the percentage of patients, while the x-axis lists the rating categories from Markedly Improved to Markedly Worse.*

FDA Label Image

Figure 10 (Zunveyl 11)

A line graph showing mean change from baseline in ADAS-cog score over 13 weeks of treatment. One line represents placebo with minimal improvement or decline, and the other represents 24 or 32 mg/day dose showing notable improvement by week 4 maintained through week 13. Error bars indicate standard error on each data point.*

FDA Label Image

Figure 11 (Zunveyl 12)

A cumulative percentage graph showing the change from baseline in ADAS-cog scores for patients receiving either placebo or 24 or 32 mg/day of a treatment. The x-axis represents the ADAS-cog change from baseline, ranging from -15 to 15 points, with vertical lines marking -10, -7, -4 points, and no change at 0. The y-axis shows the cumulative percentage of patients from 0% to 100%. The graph compares the two groups, indicating differences in cognitive change outcomes.*

FDA Label Image

Figure 12 (Zunveyl 13)

Bar chart comparing the percentage of patients by CIBIC-plus Rating categories for placebo versus 24 or 32 mg/day dosage groups. The categories range from Markedly Improved to Markedly Worse with corresponding percentages on the vertical axis. The chart shows data distribution for both treatment and placebo groups.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Label for ZUNVEYL 5 mg delayed release tablets containing benzgalantamine, manufactured by Alpha Cognition, Inc. The label includes dosage storage instructions, child resistance warnings, and patient resources contact information. The package contains 60 tablets for oral use.*

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Label for ZUNVEYL (benzgalantamine) delayed release tablets, 10 mg strength. The label indicates a package size of 60 tablets and includes storage instructions, manufacturer Alpha Cognition, Inc., and a barcode. It also provides patient resources with a website and phone number.*

FDA Label Image

Principal Display Panel (15 mg Tablet Bottle Label)

Label for ZUNVEYL delayed release tablets containing 15 mg benzgalantamine, manufactured by Alpha Cognition, Inc. The label indicates a package size of 60 tablets and includes storage instructions, child safety information, and patient resource contact details. The label features the ZUNVEYL logo with a sunburst design.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.